Tom's of Maine: Company extends its anticavity line with new Natural Anticavity plus Whitening fluoride toothpastes in both gel and liquid gel formulations. Silica, a mild abrasive derived from sand, provides products with natural whitening power without bleaching or harsh abrasives, Kennebunk, Maine-based firm says. Gel versions, sold in 5.5 oz tubes with an SRP of $4.79, come in five flavors including spearmint, peppermint, cinnamint, orange-mango and wintermint. Liquid gel toothpastes in peppermint, spearmint, cinnamint, and fennel flavors come in two sizes: 4.58 oz. and travel-convenient 1.5 oz carry SRPs of $4.49 and $2.79, respectively. Launch began in January and will continue through March. Both varieties will be available in 50,000 health and mass retail locations by May...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.
The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.
